SCHEMBL10141846

SCHEMBL10141846

CC(C)=CCC/C(C)=C/COc1ccccc1C=O

nearest known ligand 0.55

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALOX15 P16050 7/20 0.55
ALDH1A1 P00352 2/20 0.50
PTGDR2 Q9Y5Y4 1/20 0.50
HPGD P15428 1/20 0.50
HTT P42858 1/20 0.50
SMN1; SMN2 Q16637 1/20 0.50
TRPV1 Q8NER1 1/20 0.49
PTGES O14684 2/20 0.47
NDUFS8 O00217 1/20 0.47
COXFA4 O00483 1/20 0.47
NDUFAB1 O14561 1/20 0.47
NDUFA1 O15239 1/20 0.47
NDUFS4 O43181 1/20 0.47
NDUFB5 O43674 1/20 0.47
NDUFB3 O43676 1/20 0.47
NDUFC1 O43677 1/20 0.47
NDUFA2 O43678 1/20 0.47
NDUFS5 O43920 1/20 0.47
NDUFS7 O75251 1/20 0.47
NDUFS2 O75306 1/20 0.47

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL31618356 1.00 ALOX15 (0.55) ALOX15ALDH1A1PTGDR2HPGDHTT
SCHEMBL4241452 0.87 ALDH1A1 (0.61) ALDH1A1PTGDR2HPGDHTTSMN1; SMN2
SCHEMBL25429264 0.86 ALOX15 (0.52) ALOX15TRPV1PTGESNDUFS8COXFA4
SCHEMBL24183222 0.85 ALOX15 (0.61) ALOX15TRPV1PTGESNDUFS8COXFA4
SCHEMBL8203204 0.81 PTGES (0.59) ALOX15TRPV1PTGESNDUFS8COXFA4
SCHEMBL4556002 0.80 ALOX15 (0.55) ALOX15TRPV1PTGESNDUFS8COXFA4
SCHEMBL26501138 0.80 TRPV1 (0.43) ALOX15TRPV1
SCHEMBL4556003 0.80 ALOX15 (0.55) ALOX15TRPV1PTGESNDUFS8COXFA4
SCHEMBL8215581 0.80 PTGES (0.60) ALOX15TRPV1PTGESNDUFS8COXFA4
SCHEMBL26500837 0.80 KDM4E (0.44) ALDH1A1PTGDR2HPGDHTTSMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2655344-B1 NOVEL PHENAZINE DERIVATIVES AND THEIR USE UNIV CATHOLIQUE LOUVAIN (BE) 2015-11-25 EP disclosed
US-9181265-B2 Substituted 2,3-dihydro-1H-benzo[a]pyrano[2,3-c]phenazines as anti-angiogenic and anti-cancer agents UNIVERSITE CATHOLIQUE DE LOUVAIN (BE) 2015-11-10 US disclosed
US-9181265-B2 Substituted 2,3-dihydro-1H-benzo[a]pyrano[2,3-c]phenazines as anti-angiogenic and anti-cancer agents UNIVERSITE CATHOLIQUE DE LOUVAIN (BE) 2015-11-10 US disclosed
US-20130289030-A1 NOVEL PHENAZINE DERIVATIVES AND THEIR USES UNIVERSITE LIBRE DE BRUXELLES (BE) 2013-10-31 US disclosed
US-20130289030-A1 NOVEL PHENAZINE DERIVATIVES AND THEIR USES UNIVERSITE LIBRE DE BRUXELLES (BE) 2013-10-31 US disclosed
WO-2012085222-A1 NOVEL PHENAZINE DERIVATIVES AND THEIR USE UNIVERSITE CATHOLIQUE DE LOUVAIN (BE) 2012-06-28 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20130289030-A1 NOVEL PHENAZINE DERIVATIVES AND THEIR USES VEGFA, KDR, FLT4 ALOX15 2092/4885ALDH1A1 671/4885PTGDR2 62/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.